Vapogenix Awarded $1.5M Phase II SBIR grant to develop topical therapy for Painful Inflammatory Conditions


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Vapogenix Awarded $1.5M Phase II SBIR grant to develop topical therapy for Painful Inflammatory Conditions
This work will allow Vapogenix to meet with the U.S. Food and Drug Administration (FDA) to finalize an Investigational New Drug (IND)-application

Vapogenix, a clinical-stage company developing a new class of topical non-opioid, lidocaine-free analgesics, announced it has been awarded a $1.5M Phase II Small Business Innovation Research (SBIR) grant (Award No. R44AR074838) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the US National Institutes of Health.

The grant supports Vapogenix’s development of a novel topical medicine, based on the unique analgesic and anti-inflammatory properties of volatile anesthetics (VAs) to treat inflammatory pain associated with musculoskeletal diseases such as rheumatoid arthritis, gout and osteoarthritis, which affect millions of Americans.

Successful Phase I SBIR studies, conducted at Vapogenix and Texas Heart Institute (THI), Houston, TX, demonstrated that VAs had anti-inflammatory properties, in addition to previously described analgesic effects. The Phase II SBIR funding will be used to develop a formulation of VPX638 (sevoflurane) and to further characterize the anti-inflammatory and analgesic profile in animal disease models. This work will allow Vapogenix to meet with the U.S. Food and Drug Administration (FDA) to finalize an Investigational New Drug (IND)-application, and to progress to clinical studies of a novel topical anti-inflammatory product.

“We are developing a much needed new product with a novel dual mechanism, good efficacy and excellent safety profile. There is a real clinical imperative to develop alternatives to opioids for the more than 30 million patients suffering from painful inflammatory conditions. We would like to express our thanks to NIAMS for making this award,” said Vapogenix CEO Heather Giles, PhD.

Topical formulated VPX638 is expected to offer an effective and safer alternative to current therapies such as nonsteroidal anti-inflammatory drugs (NSAIDS) and opioids, which come with serious side effects.

“This work is a case study in following new scientific discoveries to re-purpose already approved drugs. We previously demonstrated that VAs can inhibit the function of leukocyte cell adhesion receptors that are responsible for generating an inflammatory response. By formulating these VAs, Vapogenix can now develop new treatment options for safe and effective pain management using a single, dual-action agent,” added Darren Woodside, PhD, Vice President of Research at Texas Heart Institute.

VPX638 formulation for painful inflammatory conditions is among Vapogenix’s platform of novel, patented formulations of VAs, being developed for the localized treatment of a broad range of painful conditions, including wounds, combat-related injuries, and medical procedures such as needle injections, needle biopsies and cosmetic dermatology.

Last year Vapogenix announced results of a Phase 2 clinical trial of VPX638 which demonstrated rapid onset and sustained duration of pain relief and reduced opioid use for patients with painful wounds. Dr. Giles stated “We are seeking additional funding and partners to get these much-needed products into the market”

Tags : #Vapogenix #SBIRGrant #TopicalTherapyforInflammation #FDA #latestPharmaNewsNov13

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026